Ocular Therapeutix (OCUL) Interest & Investment Income (2013 - 2026)
Ocular Therapeutix's quarterly Interest & Investment Income came in at $6.0 million in Q1 2026, up 58.13% year-on-year from $3.8 million in Q1 2025, and down 17.61% quarter-over-quarter from $7.3 million in Q4 2025.
Ocular Therapeutix has reported Interest & Investment Income for 14 years, with the latest figure at $6.0 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 58.13% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.6 million (up 1.94% YoY), and the FY2025 full-year result was $18.4 million, down 9.5% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $6.0 million, down from $7.3 million in the prior quarter.
- The five-year high for Interest & Investment Income was $7.3 million in Q4 2025, with the low at $18000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $2.9 million, with a median of $3.5 million recorded in 2025.
- Year-over-year, Interest & Investment Income soared 6950.0% in 2022 and tumbled 42.76% in 2025.
- Tracing OCUL's Interest & Investment Income over 5 years: stood at $423000.0 in 2022, then surged by 244.92% to $1.5 million in 2023, then jumped by 220.15% to $4.7 million in 2024, then surged by 57.2% to $7.3 million in 2025, then declined by 17.61% to $6.0 million in 2026.
- The last three Interest & Investment Income figures came in at $6.0 million (Q1 2026), $7.3 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 6.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 7.34 Mn |
| Sep 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 3.46 Mn |
| Mar 31, 2025 | 3.83 Mn |
| Dec 31, 2024 | 4.67 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 6.04 Mn |
| Mar 31, 2024 | 3.92 Mn |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | 748,000.00 |
| Mar 31, 2023 | 563,000.00 |
| Dec 31, 2022 | 423,000.00 |
| Sep 30, 2022 | 285,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Mar 31, 2022 | 18,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 8,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Sep 30, 2020 | 6,000.00 |
| Jun 30, 2020 | 17,000.00 |
| Mar 31, 2020 | 139,000.00 |
| Dec 31, 2019 | 213,000.00 |
| Sep 30, 2019 | 308,000.00 |
| Jun 30, 2019 | 379,000.00 |
| Mar 31, 2019 | 329,000.00 |
| Dec 31, 2018 | 258,000.00 |
| Sep 30, 2018 | 230,000.00 |
| Jun 30, 2018 | 215,000.00 |
| Mar 31, 2018 | 176,000.00 |
| Dec 31, 2017 | 104,000.00 |
| Sep 30, 2017 | 115,000.00 |
| Jun 30, 2017 | 113,000.00 |
| Mar 31, 2017 | 92,000.00 |
| Dec 31, 2016 | 68,000.00 |
| Sep 30, 2016 | 69,000.00 |
| Jun 30, 2016 | 80,000.00 |
| Mar 31, 2016 | 87,000.00 |
| Dec 31, 2015 | 45,000.00 |
| Sep 30, 2015 | 53,000.00 |
| Jun 30, 2015 | 28,000.00 |
| Mar 31, 2015 | 40,000.00 |
| Sep 30, 2014 | 5,000.00 |
| Jun 30, 2014 | 1,000.00 |
| Mar 31, 2014 | 1,000.00 |
| Dec 31, 2013 | 2,000.00 |
| Sep 30, 2013 | 3,000.00 |
| Jun 30, 2013 | 3,000.00 |